X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2865) 2865
Book Review (820) 820
Publication (270) 270
Book Chapter (15) 15
Conference Proceeding (10) 10
Magazine Article (4) 4
Dissertation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2288) 2288
cetuximab (2247) 2247
humans (2207) 2207
oncology (1875) 1875
colorectal cancer (1398) 1398
chemotherapy (1209) 1209
colorectal neoplasms - drug therapy (1193) 1193
female (1074) 1074
male (1051) 1051
cancer (993) 993
middle aged (949) 949
aged (901) 901
colorectal neoplasms - pathology (868) 868
1st-line treatment (766) 766
antineoplastic combined chemotherapy protocols - therapeutic use (757) 757
bevacizumab (699) 699
adult (695) 695
metastasis (686) 686
colorectal neoplasms - genetics (675) 675
antineoplastic agents - therapeutic use (664) 664
antibodies, monoclonal, humanized (657) 657
mutation (624) 624
growth-factor receptor (611) 611
antibodies, monoclonal - therapeutic use (607) 607
care and treatment (590) 590
fluorouracil (583) 583
panitumumab (583) 583
oxaliplatin (580) 580
treatment outcome (579) 579
receptor, epidermal growth factor - antagonists & inhibitors (518) 518
irinotecan (496) 496
cetuximab plus irinotecan (493) 493
metastatic colorectal-cancer (465) 465
leucovorin (464) 464
kras (458) 458
camptothecin - analogs & derivatives (453) 453
neoplasm metastasis (447) 447
aged, 80 and over (423) 423
research (422) 422
ras proteins - genetics (416) 416
antibodies, monoclonal - administration & dosage (408) 408
disease-free survival (406) 406
egfr (393) 393
prognosis (383) 383
proto-oncogene proteins p21 (381) 381
epidermal growth factor (377) 377
therapy (374) 374
drug therapy (370) 370
proto-oncogene proteins - genetics (369) 369
tumors (368) 368
monoclonal antibodies (359) 359
medicine & public health (358) 358
survival (357) 357
phase-iii trial (354) 354
camptothecin - administration & dosage (336) 336
analysis (328) 328
plus irinotecan (328) 328
digestive system diseases (314) 314
pharmacology & pharmacy (306) 306
health aspects (305) 305
colorectal neoplasms - mortality (304) 304
fluorouracil - administration & dosage (294) 294
hematology, oncology and palliative medicine (292) 292
genetic aspects (287) 287
neoplasms (278) 278
antineoplastic agents (275) 275
trial (274) 274
cancer therapies (270) 270
antibodies, monoclonal - adverse effects (267) 267
metastatic colorectal cancer (264) 264
receptor, epidermal growth factor - metabolism (264) 264
open-label (262) 262
antineoplastic combined chemotherapy protocols - adverse effects (261) 261
antimitotic agents (260) 260
animals (256) 256
cell lung-cancer (251) 251
expression (248) 248
retrospective studies (246) 246
organoplatinum compounds - administration & dosage (242) 242
patients (238) 238
liver neoplasms - secondary (234) 234
clinical trials (227) 227
antineoplastic agents - adverse effects (223) 223
phase-ii trial (223) 223
surgery (220) 220
antineoplastic combined chemotherapy protocols - administration & dosage (218) 218
cancer research (218) 218
proto-oncogene proteins b-raf - genetics (215) 215
combination (207) 207
braf (205) 205
colorectal carcinoma (201) 201
metastases (199) 199
colon-cancer (197) 197
antineoplastic agents - pharmacology (194) 194
epidermal growth factor receptor (193) 193
neoplasm staging (191) 191
survival rate (190) 190
colorectal neoplasms - metabolism (189) 189
capecitabine (188) 188
cancer patients (184) 184
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2798) 2798
French (31) 31
German (22) 22
Japanese (15) 15
Spanish (4) 4
Chinese (3) 3
Korean (2) 2
Italian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2004, Volume 351, Issue 4, pp. 337 - 345
In this randomized trial, cetuximab, a monoclonal antibody against the epidermal growth factor receptor, was given alone or in combination with irinotecan to... 
CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER RANDOMIZED-TRIAL | PHASE-II TRIAL | TYROSINE KINASE | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | FLUOROURACIL-LEUCOVORIN | RESISTANT CHINESE-HAMSTER | Single-Blind Method | Adenocarcinoma - pathology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Topoisomerase I Inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | Dosage and administration | Drug therapy, Combination | Research | Drug therapy | Colorectal cancer | Nuclear magnetic resonance--NMR | Epidermal growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2008, Volume 26, Issue 14, pp. 2311 - 2319
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2009, Volume 101, Issue 4, pp. 715 - 721
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 132 - 140
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2622 - 2629
Purpose PTEN, AKT, and KRAS are epidermal growth factor receptor (EGFR) downstream regulators. KRAS mutations confer resistance to cetuximab. This... 
CELL LUNG-CANCER | PANITUMUMAB | K-RAS MUTATIONS | THERAPY | GROWTH-FACTOR-RECEPTOR | EFFICACY | ONCOLOGY | SIGNALING PATHWAY | RESISTANCE | EGFR | CHEMOTHERAPY | Immunohistochemistry | Predictive Value of Tests | ras Proteins - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | PTEN Phosphohydrolase - analysis | Drug Resistance, Neoplasm | Male | Patient Selection | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Phytogenic - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Colorectal Neoplasms - enzymology | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins c-akt - analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Colorectal Neoplasms - secondary | Italy - epidemiology | Aged | Mutation | Longitudinal Studies | Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2016, Volume 138, Issue 3, pp. 739 - 746
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1427 - 1434
Purpose Regulation of epidermal growth factor receptor (EGFR) signaling pathways may play a relevant role in determining the activity of cetuximab therapy in... 
DEPENDENT CELLULAR CYTOTOXICITY | LUNG-CANCER | CELLS | FUNCTIONAL POLYMORPHISM | FACTOR RECEPTOR EGFR | ONCOLOGY | EPIDERMAL-GROWTH-FACTOR | DINUCLEOTIDE REPEAT POLYMORPHISM | INTRON-1 POLYMORPHISM | MODULATION | GENE-TRANSCRIPTION | Haplotypes | Leucovorin - administration & dosage | Receptor, Epidermal Growth Factor - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Cetuximab | Gene Expression Regulation, Neoplastic - genetics | Camptothecin - analogs & derivatives | Drug Administration Schedule | Proportional Hazards Models | Signal Transduction - genetics | Genetic Markers | Disease Progression | Polymorphism, Genetic | Disease-Free Survival | Analysis of Variance | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Colorectal Neoplasms - pathology | Salvage Therapy - methods | Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2017, Volume 140, Issue 9, pp. 2162 - 2167
Journal Article